(REGN) Regeneron Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Eye, Dermatology, Asthma, Cancer, Arthritis

Stock: Biotechnology
Age 34.8y
MCap 78,634m
Avg Vol 789K (585M USD)
Beta 0.563
Volatility 33.97%

EPS (Earnings per Share)

EPS (Earnings per Share) of REGN over the last years for every Quarter: "2020-12": 9.53, "2021-03": 9.89, "2021-06": 25.8, "2021-09": 14.37, "2021-12": 21.32, "2022-03": 8.93, "2022-06": 9.77, "2022-09": 11.14, "2022-12": 12.56, "2023-03": 10.09, "2023-06": 10.24, "2023-09": 11.59, "2023-12": 11.86, "2024-03": 9.55, "2024-06": 11.56, "2024-09": 12.46, "2024-12": 12.07, "2025-03": 8.22, "2025-06": 12.89, "2025-09": 11.83, "2025-12": 0,
EPS CAGR: -44.12%
EPS Trend: -36.7%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of REGN over the last years for every Quarter: 2020-12: 2422.9, 2021-03: 2528.7, 2021-06: 5138.5, 2021-09: 3452.8, 2021-12: 4951.7, 2022-03: 2965.1, 2022-06: 2857.2, 2022-09: 2936.2, 2022-12: 3414.4, 2023-03: 3162.1, 2023-06: 3158.1, 2023-09: 3362.7, 2023-12: 3434.3, 2024-03: 3145, 2024-06: 3547.1, 2024-09: 3720.7, 2024-12: 3789.2, 2025-03: 3028.7, 2025-06: 3675.6, 2025-09: 3754.3, 2025-12: null,
Rev. CAGR: -7.12%
Rev. Trend: 15.0%
Last SUE: 0.91
Qual. Beats: 2

Dividends

Dividend Yield 0.54%
Yield on Cost 5y 0.65%
Yield CAGR 5y 0.00%
Payout Consistency 100.0%
Payout Ratio 7.8%
Risk via 5d forecast
Volatility 34.0%
Value at Risk 5%th 51.2%
Relative Tail Risk -8.42%
Reward TTM
Sharpe Ratio 0.32
Alpha 1.19
CAGR/Max DD 0.01
Character TTM
Hurst Exponent 0.348
Beta 0.563
Beta Downside 0.320
Drawdowns 3y
Max DD 59.69%
Mean DD 21.54%
Median DD 10.12%

Description: REGN Regeneron Pharmaceuticals December 03, 2025

Regeneron Pharmaceuticals (NASDAQ: REGN) is a U.S. biotech firm that discovers, invents, develops, manufactures, and commercializes a broad portfolio of injectable medicines across ophthalmology, immunology, oncology, cardiovascular, infectious disease, and rare-disease markets. Its flagship products include EYLEA for retinal disorders, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous-cell carcinoma, and the COVID-19 antibody cocktail REGEN-COV, among dozens of other specialty therapies.

As of FY 2023, Regeneron reported $13.3 billion in revenue, driven primarily by EYLEA (≈ $5 billion) and Dupixent (≈ $3 billion). The company reinvested roughly $3.1 billion in R&D, reflecting a pipeline of ~ 20 late-stage candidates and multiple CRISPR-gene-editing collaborations (e.g., Mammoth Biosciences). Key sector drivers that influence its outlook are the aging-population-induced demand for ophthalmic and cardiovascular drugs, the expanding market for biologics in immunology, and the industry-wide shift toward gene-editing platforms, which could materially affect future growth trajectories.

For a deeper quantitative dive, you might explore ValueRay’s analyst tools to assess Regeneron’s valuation dynamics.

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income: 4.58b TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.32 > 1.0
NWC/Revenue: 95.14% < 20% (prev 113.2%; Δ -18.04% < -1%)
CFO/TA 0.13 > 3% & CFO 5.07b > Net Income 4.58b
Net Debt (199.1m) to EBITDA (5.71b): 0.03 < 3
Current Ratio: 4.06 > 1.5 & < 3
Outstanding Shares: last quarter (107.2m) vs 12m ago -7.75% < -2%
Gross Margin: 85.39% > 18% (prev 0.85%; Δ 8454 % > 0.5%)
Asset Turnover: 36.72% > 50% (prev 36.98%; Δ -0.27% > 0%)
Interest Coverage Ratio: 123.2 > 6 (EBITDA TTM 5.71b / Interest Expense TTM 42.1m)

Altman Z'' 9.96

A: 0.34 (Total Current Assets 17.98b - Total Current Liabilities 4.43b) / Total Assets 40.17b
B: 0.87 (Retained Earnings 35.05b / Total Assets 40.17b)
C: 0.13 (EBIT TTM 5.19b / Avg Total Assets 38.81b)
D: 3.81 (Book Value of Equity 35.11b / Total Liabilities 9.21b)
Altman-Z'' Score: 9.96 = AAA

Beneish M -2.99

DSRI: 0.91 (Receivables 5.69b/6.11b, Revenue 14.25b/13.85b)
GMI: 1.00 (GM 85.39% / 85.31%)
AQI: 1.17 (AQ_t 0.43 / AQ_t-1 0.37)
SGI: 1.03 (Revenue 14.25b / 13.85b)
TATA: -0.01 (NI 4.58b - CFO 5.07b) / TA 40.17b)
Beneish M-Score: -2.99 = A

ValueRay F-Score (Strict, 0-100) 75.35

1. Piotroski: 7.50pt
2. FCF Yield: 5.70%
3. FCF Margin: 29.16%
4. Debt/Equity: 0.09
5. Debt/Ebitda: 0.03
6. ROIC - WACC: 5.72%
7. RoE: 15.31%
8. Revenue Trend: 15.02%
9. EPS Trend: -36.72%

What is the price of REGN shares?

As of January 25, 2026, the stock is trading at USD 753.55 with a total of 676,321 shares traded.
Over the past week, the price has changed by +2.80%, over one month by -4.03%, over three months by +31.06% and over the past year by +9.08%.

Is REGN a buy, sell or hold?

Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the REGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 826 9.6%
Analysts Target Price 826 9.6%
ValueRay Target Price 762 1.1%

REGN Fundamental Data Overview January 24, 2026

P/E Trailing = 17.7918
P/E Forward = 16.8634
P/S = 5.519
P/B = 2.5188
P/EG = 1.411
Revenue TTM = 14.25b USD
EBIT TTM = 5.19b USD
EBITDA TTM = 5.71b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 199.1m USD (from netDebt column, last quarter)
Enterprise Value = 72.90b USD (78.63b + Debt 2.71b - CCE 8.44b)
Interest Coverage Ratio = 123.2 (Ebit TTM 5.19b / Interest Expense TTM 42.1m)
EV/FCF = 17.55x (Enterprise Value 72.90b / FCF TTM 4.15b)
FCF Yield = 5.70% (FCF TTM 4.15b / Enterprise Value 72.90b)
FCF Margin = 29.16% (FCF TTM 4.15b / Revenue TTM 14.25b)
Net Margin = 32.13% (Net Income TTM 4.58b / Revenue TTM 14.25b)
Gross Margin = 85.39% ((Revenue TTM 14.25b - Cost of Revenue TTM 2.08b) / Revenue TTM)
Gross Margin QoQ = 86.11% (prev 85.58%)
Tobins Q-Ratio = 1.81 (Enterprise Value 72.90b / Total Assets 40.17b)
Interest Expense / Debt = 0.71% (Interest Expense 19.3m / Debt 2.71b)
Taxrate = 17.20% (303.3m / 1.76b)
NOPAT = 4.29b (EBIT 5.19b * (1 - 17.20%))
Current Ratio = 4.06 (Total Current Assets 17.98b / Total Current Liabilities 4.43b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 30.96b)
Debt / EBITDA = 0.03 (Net Debt 199.1m / EBITDA 5.71b)
Debt / FCF = 0.05 (Net Debt 199.1m / FCF TTM 4.15b)
Total Stockholder Equity = 29.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.80% (Net Income 4.58b / Total Assets 40.17b)
RoE = 15.31% (Net Income TTM 4.58b / Total Stockholder Equity 29.91b)
RoCE = 16.26% (EBIT 5.19b / Capital Employed (Equity 29.91b + L.T.Debt 1.99b))
RoIC = 13.47% (NOPAT 4.29b / Invested Capital 31.89b)
WACC = 7.74% (E(78.63b)/V(81.34b) * Re(7.99%) + D(2.71b)/V(81.34b) * Rd(0.71%) * (1-Tc(0.17)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.94%
[DCF Debug] Terminal Value 76.49% ; FCFF base≈3.84b ; Y1≈3.26b ; Y5≈2.49b
Fair Price DCF = 459.6 (EV 47.67b - Net Debt 199.1m = Equity 47.47b / Shares 103.3m; r=7.74% [WACC]; 5y FCF grow -18.28% → 2.90% )
EPS Correlation: -36.72 | EPS CAGR: -44.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: 15.02 | Revenue CAGR: -7.12% | SUE: 0.91 | # QB: 2
EPS next Quarter (2026-03-31): EPS=10.24 | Chg30d=-0.187 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=39.56 | Chg30d=+1.199 | Revisions Net=+3 | Growth EPS=-3.1% | Growth Revenue=+7.9%

Additional Sources for REGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle